Literature DB >> 6808170

Hyperammonemia during total parenteral nutrition in children.

J H Seashore, M R Seashore, C Riely.   

Abstract

Serial blood ammonia (NH3) determinations in 19 low birth weight (LBW) infants, 14 term neonates and 12 children receiving total parenteral nutrition (TPN) have shown that 73% of patients had one or more elevated NH3 values (greater than 150 micrograms/dl). The mean blood NH3 was 220 +/- 13 micrograms/dl in LBW infants, 180 +/- 9 micrograms/dl in 10 infants, and 140 +/- 7 micrograms/dl in children. All of these values are significantly higher than normal (p less than 0.001). There was no difference in incidence or mean blood ammonia concentration between patients receiving casein hydrolysate and those receiving a crystalline amino acid solution. Only four patients were symptomatic and several infants remained fully alert despite blood NH3 concentration in excess of 400 micrograms/dl. One infant who had sustained hyperammonemia was given another amino acid source (Travasol) containing 1.2 mmol/dl of arginine; blood NH3 promptly fell to the normal range. However, six of seven additional infants had hyperammonemia while receiving Travasol (mean = 184 micrograms/dl). Hyperammonemia is common during TPN in children, often is not recognized clinically, and occurs with equal frequency in infants and older children. The high levels observed in LBW infants may be due to hepatic immaturity. Blood NH3 concentration should be monitored frequently during TPN. Persistent hyperammonemia should be treated by decreasing protein content of the infusate. The role of supplemental arginine is unclear.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6808170     DOI: 10.1177/0148607182006002114

Source DB:  PubMed          Journal:  JPEN J Parenter Enteral Nutr        ISSN: 0148-6071            Impact factor:   4.016


  2 in total

1.  Hyperammonemic encephalopathy caused by carnitine deficiency.

Authors:  Berkeley N Limketkai; Stephen D Zucker
Journal:  J Gen Intern Med       Date:  2007-12-13       Impact factor: 5.128

2.  Clinical Relevance and Cost-Savings of Levocarnitine Versus Ammonul in the Management Of Hyperammonemia in a Cancer Patient: The Impact of a Clinical Pharmacist.

Authors:  Chukwuma Anyanwu; Chinonso Ezeudu; Hoa Le; Oliver Egwim
Journal:  P T       Date:  2018-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.